Maternal and newborn outcomes following paliperidone palmitate use during pregnancy and puerperal period in two women with schizophrenia

2016-12-30T05-45-32Z
Source: Cukurova Medical Journal
Esin Erdoğan, Dursun Hakan Delibaş, Sevilay Ozcan, Ilker Erdoğan, Ozen Onen Sertoz.
Use of long-acting antipsychotics in schizophrenia provides advantages in achievement of compliance to treatment and maintenance of treatment. There is limited information on use of Paliperidone Palmitate (PP) during period of pregnancy and puerperality. Here, it was reported that two cases with schizophrenia who used PP during period of pregnancy, at the term, had healthy and vaginal delivery and then continued to use PP for a while including period of puerperium. The assessment of infant development included pediatric examination, physical and neurobehavioral development measurements at 2, 6, 12, 18 and 24 months of age. In our cases, no specific risks for the mothers and their children can be attributed to the use of PP during monitoring period. A clear plan for a woman and her supports (partner and family as appropriate) for postpartum care is essential for ongoing monitoring and care. Although it was not reported that fetus exposed to antipsychotics had congenital malformation; it should be kept in mind that in the future these children can develop neurodevelopmental and neurobehavioral problems.


from Scope via xlomafota13 on Inoreader http://ift.tt/2hwpt0U
via IFTTT